Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that, in connection with the appointment of Jason V. O’Byrne as Chief Financial Officer effective August 11, 2026, the Company granted Mr. O’Byrne an employment inducement award consisting of stock options to purchase 650,000 shares of the Company’s common stock, with an effective grant date of September 1, 2026 and an exercise price of $10.56 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on September 1, 2026. The award was approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan. The stock options vest over four years, with 25 percent vesting on August 11, 2027 and the remainder vesting in 36 equal monthly installments over the following three years, subject to continuous employment as of such vesting dates.
- Xilio Therapeutics, Inc.Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Waterfall ScientificWaterfall Scientific Awarded Up to $54.5 Million from ARPA-H to Lead Consortium Developing Continuous-Flow Cell-Free mRNA Manufacturing and Characterization PlatformWORCESTER, Mass., September 02, 2026--Waterfall Scientific, a biotechnology company pioneering continuous-flow RNA manufacturing technologies, today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to lead a six-company consortium under the Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. The project, titled ESCALATOR, brings together a network of industry leaders in cell-free nucleic acid synthesis, LNP formulation,
- Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature CommunicationsTransgene and NEC Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
- Thyme CareThyme Care Closes $125+ Million Series E, Establishes Thyme Companies to Broaden Its Impact Across the Oncology EcosystemMorgan Health, CVS Health Ventures, and Humana, alongside other strategic payers and providers, invest in Thyme Care at a valuation of more than $2B The new capital accelerates Thyme Care's continued growth and establishes Thyme Companies, a newly formed parent entity building a broader...
- Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)Company announcement No. 45 / 2026
- SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK StrategiesThis strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment options for adult Tourette Syndrome
- Rigel Pharmaceuticals, Inc.Rigel to Participate in Upcoming September Investor ConferencesRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the...
- Encapsulated Lactic Acid Market Analysis Report 2026-2031 - Advanced Coating Technologies Expand Specialty ApplicationsOpportunities center on nutraceuticals, probiotics, liquid formats and clean-label plant coatings, while controlled-release innovation expands food, beverage and pharmaceutical uses
- NewAmsterdam PharmaNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in SeptemberNewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
- Annexon BiosciencesAnnexon to Participate in Upcoming September Investor ConferencesAnnexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: